Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema).[1]
The most common side effects include injection site reactions, dry eye and conjunctivitis (redness and discomfort in the eye) including allergic conjunctivitis.[1]
It was approved for medical use in the European Union in November 2023.[1]
^ abcd"Ebglyss EPAR". European Medicines Agency (EMA). 21 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Ebglyss Product information". Union Register of medicinal products. 17 November 2023. Archived from the original on 26 November 2023. Retrieved 11 December 2023.
Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). The most...
hypereosinophilic leukemia Monoclonal antibodies such as dupilumab and lebrikizumab target IL-13 and its receptor, which reduces eosinophilic inflammation...
that use anti-IL-13 monoclonal antibodies include tralokinumab, and lebrikizumab. These treatments have shown improvements in asthma patients, yet there...
Dermira for $1.1 billion, gaining control of two key assets, among others; lebrikizumab and glycopyrronium cloth used to treat hyperhidrosis. In June 2020, the...
are approved to treat moderate-to-severe eczema in the US and the EU. Lebrikizumab (Ebglyss) is also approved in the EU for treating moderate-to-severe...
for IPF, including the monoclonal antibodies simtuzumab, tralokinumab, lebrikizumab and FG-3019, a lysophosphatidic acid receptor antagonist (BMS-986020)...
Global Information
(what is this?) (verify)